bhv-1530
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2025 (NCT06874335)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
Chemistry & pharmacology
- Payload
- TopoIx
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06874335 | Phase 1 | Mar 20, 2025 | Biohaven Pharmaceuticals Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biohaven Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1